ATGG.F Stock Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.015 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.013 |
| Beta | 2.31 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -85.00% |
| 3 Year Change | n/a |
| 5 Year Change | -70.00% |
| Change since IPO | -70.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| ATGG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | -3.7% |
| 1Y | -85.0% | -2.7% | 20.2% |
Return vs Industry: ATGG.F underperformed the US Biotechs industry which returned 3.3% over the past year.
Return vs Market: ATGG.F underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| ATGG.F volatility | |
|---|---|
| ATGG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATGG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATGG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | www.actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer’s disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| ATGG.F fundamental statistics | |
|---|---|
| Market cap | US$34.52m |
| Earnings (TTM) | -US$7.31m |
| Revenue (TTM) | US$3.32m |
10.4x
P/S Ratio-4.7x
P/E RatioIs ATGG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATGG.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.89m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$4.89m |
| Other Expenses | AU$15.64m |
| Earnings | -AU$10.75m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0047 |
| Gross Margin | 100.00% |
| Net Profit Margin | -219.98% |
| Debt/Equity Ratio | 0% |
How did ATGG.F perform over the long term?
See historical performance and comparison